Corpus ID: 14171061

Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer

@inproceedings{Tarhini2010CancerT,
  title={Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer},
  author={A. Tarhini and A. Kotsakis and W. Gooding and Y. Shuai and D. Petro and D. Friedland and C. Belani and S. Dacic and A. Argiris},
  year={2010}
}
  • A. Tarhini, A. Kotsakis, +6 authors A. Argiris
  • Published 2010
  • Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed 

    Figures and Tables from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 39 REFERENCES
    Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
    • 108
    • Highly Influential
    Progress in the therapy of small cell lung cancer.
    • 81
    New guidelines to evaluate the response to treatment in solid tumors
    • 3,358
    • Highly Influential
    • PDF